Disease · MONDO_0004980
Comparisons in its trials266
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 266
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pimecrolimus vs Topical Corticosteroids: serious adverse events | 247 of 1,205 | 210 of 1,213 | 2,418 | NCT00120523 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16 | 87 of 601 | 8 of 197 | 798 | NCT03131648 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16 | 156 of 601 | 23 of 197 | 798 | NCT03131648 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 | 95 of 601 | 14 of 197 | 798 | NCT03131648 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16 | 150 of 601 | 25 of 197 | 798 | NCT03131648 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16 | 250 of 601 | 42 of 197 | 798 | NCT03131648 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16 | 53 of 601 | 6 of 197 | 798 | NCT03131648 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Reduction of Worst Daily Pruritus NRS (Weekly Average) ≥3 From Baseline to Week 16 | 177 of 597 | 28 of 195 | 792 | NCT03131648 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16. | 198 of 591 | 29 of 201 | 792 | NCT03160885 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16. | 108 of 591 | 11 of 201 | 792 | NCT03160885 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16 | 295 of 591 | 41 of 201 | 792 | NCT03160885 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI]. | 196 of 591 | 23 of 201 | 792 | NCT03160885 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16. | 131 of 591 | 22 of 201 | 792 | NCT03160885 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16. | 68 of 591 | 7 of 201 | 792 | NCT03160885 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16. | 119 of 594 | 20 of 194 | 788 | NCT03131648 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Reduction of Worst Daily Pruritus NRS (Weekly Average) ≥3 From Baseline to Week 16. | 199 of 583 | 28 of 200 | 783 | NCT03160885 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16. | 144 of 575 | 19 of 200 | 775 | NCT03160885 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of ≥4 Points Among Subjects With Baseline DLQI ≥4. | 325 of 577 | 54 of 198 | 775 | NCT03160885 | Trial comparisons |
| Tralokinumab 300 mg Q2W vs Placebo Q2W: Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of ≥4 Points Among Subjects With Baseline DLQI ≥4 | 258 of 578 | 60 of 190 | 768 | NCT03131648 | Trial comparisons |
| AN2728 Ointment, 2 Percent (%) vs AN2728 Ointment, Vehicle: Number of Participants With Clinically Significant Change From Baseline in Vital Signs at Day 36 | 0 of 510 | 0 of 247 | 757 | NCT02118792 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004980/comparisons